Capital Research Global Investors Sells 2,055,172 Shares of BridgeBio Pharma, Inc. $BBIO

Key Points

• Capital Research Global Investors sold 2,055,172 shares, cutting its BridgeBio stake by 51.5% to 1,933,126 shares (about 1.0% of the company) valued at roughly $100.4 million.
• Significant insider selling has occurred recently — CEO Neil Kumar sold 28,053 shares and director Randal W. Scott sold 10,000, with insiders disposing of 227,095 shares (~$16.1M) in the last quarter while retaining 18.20% ownership.
• BBP‑418 Phase‑3 FORTIFY interim analysis

Capital Research Global Investors decreased its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 51.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,933,126 shares of the company's stock after selling 2,055,172 shares during the quarter. Capital Research Global Investors owned approximately 1.00% of BridgeBio Pharma worth $100,407,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Strs Ohio grew its holdings in shares of BridgeBio Pharma by 1.1% during the third quarter. Strs Ohio now owns 18,600 shares of the company's stock worth $966,000 after purchasing an additional 200 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of BridgeBio Pharma by 28.6% in the third quarter. GAMMA Investing LLC now owns 1,020 shares of the company's stock valued at $53,000 after buying an additional 227 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its position in BridgeBio Pharma by 22.3% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company's stock worth $54,000 after buying an additional 228 shares in the last quarter. Gabelli Funds LLC grew its holdings in BridgeBio Pharma by 0.3% during the 2nd quarter. Gabelli Funds LLC now owns 73,750 shares of the company's stock worth $3,185,000 after acquiring an additional 250 shares during the last quarter. Finally, Main Management ETF Advisors LLC grew its holdings in BridgeBio Pharma by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 22,723 shares of the company's stock worth $981,000 after acquiring an additional 372 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company's stock.

Insider Buying and Selling

In other news, Director Randal W. Scott sold 10,000 shares of BridgeBio Pharma stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $75.46, for a total transaction of $754,600.00. Following the transaction, the director directly owned 11,589 shares of the company's stock, valued at $874,505.94. This trade represents a 46.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Neil Kumar sold 28,053 shares of the business's stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $71.39, for a total transaction of $2,002,703.67. Following the completion of the transaction, the chief executive officer directly owned 234,451 shares of the company's stock, valued at $16,737,456.89. This trade represents a 10.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 227,095 shares of company stock valued at $16,099,240. 18.20% of the stock is owned by company insiders.

BridgeBio Pharma Trading Down 3.9%

BridgeBio Pharma stock opened at $71.39 on Thursday. The firm has a market capitalization of $13.84 billion, a P/E ratio of -18.89 and a beta of 1.13. The business has a 50-day moving average of $73.32 and a 200-day moving average of $65.78. BridgeBio Pharma, Inc. has a 1 year low of $28.33 and a 1 year high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The company had revenue of $154.18 million for the quarter, compared to analyst estimates of $150.71 million. BridgeBio Pharma's revenue was up 2521.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.40) earnings per share. Research analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Analysts Set New Price Targets

BBIO has been the subject of a number of research analyst reports. William Blair initiated coverage on shares of BridgeBio Pharma in a research note on Tuesday. They issued an "outperform" rating for the company. Leerink Partners raised their price target on shares of BridgeBio Pharma from $75.00 to $86.00 and gave the company an "outperform" rating in a report on Monday, December 15th. Weiss Ratings restated a "sell (d-)" rating on shares of BridgeBio Pharma in a research report on Wednesday, January 21st. HC Wainwright upped their price objective on BridgeBio Pharma from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, February 17th. Finally, Truist Financial increased their price objective on BridgeBio Pharma from $86.00 to $95.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Twenty-three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, BridgeBio Pharma presently has an average rating of "Moderate Buy" and a consensus price target of $83.35.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Phase‑3 FORTIFY interim analysis for oral BBP‑418 showed early, sustained separation from placebo on ambulation endpoints (100MTT, 10MWT), favorable safety signals, and BridgeBio’s plan to submit an NDA in H1 2026 (U.S. launch targeted late‑2026/early‑2027) — a potential first approved therapy for LGMD2I/R9 if cleared. BBP-418 Phase 3 FORTIFY Interim Analysis
• Positive Sentiment: Positive conference/academic exposure — additional FORTIFY data were presented at MDA and BridgeBio participated in investor conferences (Barclays), increasing visibility among clinicians and investors. Barclays Conference Transcript
• Positive Sentiment: New/expanded analyst coverage and price‑target upgrades: William Blair initiated coverage at "Outperform" and several firms (including JPMorgan and others recently) have raised targets — supporting buy‑side momentum and higher headline valuations. William Blair Initiates Coverage
• Neutral Sentiment: HC Wainwright reiterated a Buy and $100 target but adjusted near‑term EPS forecasts (mix of upward and downward tweaks across 2026–2027), reflecting both optimism on commercial upside and uncertainty in near‑term modeling.
• Neutral Sentiment: Media coverage and short‑term trading headlines (price‑target/news driven pops and mentions on watch lists) are amplifying volume and volatility; reported short‑interest data in feeds appear inconsistent/zeroed and are not a reliable signal today.
• Negative Sentiment: Large insider selling activity noted in aggregate disclosures (multiple executives sold shares in recent months), which can weigh on investor sentiment even as clinical news is positive. Quiver Quant — Insider & Conference Summary
• Negative Sentiment: Regulatory and commercialization risk remains — interim data are promising but full NDA review, label, timing, and payer access are uncertain; investors should expect binary outcomes tied to FDA review and launch execution.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.